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Background: Self-expandable metallic stents (SEMSs) are widely used for palliation of malignant gastric outlet
obstruction (GOO). There are two types of SEMS, covered and uncovered, each with its own advantages and
disadvantages. We aimed to compare the efficacy and safety between uncovered and covered SEMSs in the
palliation of malignant gastric outlet obstruction.
Methods: Databases including PubMed, EMBASE, the Cochrane Library, the Science Citation Index and momentous
meeting abstracts were searched and evaluated by two reviewers independently.
Results: Nine trials involving 849 patients were analyzed. Meta-analysis showed there was no significant difference
in technical success rate (RR 1.0, 95% CI [0.98, 1.01]), clinical success rate (RR 1.04, 95% CI [0.98, 1.11]), post-stenting
dysphagia score (WMD −0.01, 95% CI [−0.52, 0.50]), stent patency (WMD −0.31, 95% CI [−1.73, 1.11]), overall
complications (RR 1.07, 95% CI [0.87, 1.32]) and reintervention rate (RR 1.30, 95% CI [0.92, 1.83]) between covered
and uncovered SEMSs group. However, covered SEMSs were associated with higher migration rate (RR 3.48, 95% CI
[2.16, 5.62], P < 0.00001) and lower obstruction rate (RR 0.42, 95% CI [0.24, 0.73], P = 0.002).
Conclusions: In the palliative treatment of malignant gastric outlet obstruction, both covered and uncovered
SEMSs are safely and effective. Covered stents can reduce the risk of restenosis, whereas uncovered stents are
effective in decreasing stent migration.
Keywords: Covered SEMSs, Uncovered SEMSs, Gastric outlet obstruction, Meta-analysisBackground
Malignant gastric outlet obstruction (GOO) is recognized
as a complication of advanced malignant disease in the
upper gastrointestinal tract, which usually include distal
gastric cancer, periampullary carcinoma, lymphoma and
metastases to the duodenum [1,2]. GOO always leads to in-
tractable vomiting, nausea, abdominal discomfort and poor
oral food intake, which diminish quality of life. Compared
with palliative gastrojejunostomy or other surgical proce-
dures, self-expandable metallic stents (SEMSs) can rapidly
relieve obstructive symptoms with fewer complications and
mortality [3,4]. There are two types of SEMSs, covered and* Correspondence: Panyamin2014@163.com
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unless otherwise stated.uncovered type; both of them are widely used for palli-
ation of GOO [5-7], each with its own advantages and
disadvantages.
To the best of our knowledge, a systematic review [8]
on this topic has been published. More recently, additional
studies have been published and some conflicting results
have emerged. Therefore, we believe an updated systemic
review and meta-analysis is required to evaluate the effi-
cacy and safety between uncovered and covered SEMSs
for palliation of malignant gastric outlet obstruction.Methods
Study identification and eligibility criteria
This study has been approved by ethics committee of
Shu-guang Hospital Affiliated to Shanghai University of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow diagram of trials selection. GOO, gastric outlet
obstruction; RCT, randomized clinical trial.
Pan et al. BMC Gastroenterology 2014, 14:170 Page 2 of 8
http://www.biomedcentral.com/1471-230X/14/170Traditional Chinese Medicine. A comprehensive literature
search was done to identify all relevant studies that com-
pared covered stents with uncovered stents in the palliation
of malignant gastric outlet obstruction. The PubMed,
EMBASE, the Cochrane Library and the Science Citation
Index were searched systematically for all articles published
up to Dec.2013, without language restriction, which
included the following terms in their titles, abstracts, or
keywords lists: “gastroduodenal obstruction”, “covered
stent”, “uncovered stent”, “malignant gastric outlet ob-
struction”. The references in retrieved articles were
also screened manually. The abstracts of United European
Gastroenterology week (UEGW) and Digestive Disease
Week (DDW) were also searched systematically.
The inclusion criteria were as follows: (1) RCTs and
nonrandomized prospective and retrospective studies;
(2) analyses of both uncovered stents and covered stents;
(3) patients were diagnosed malignant gastric outlet ob-
struction; (4) outcome measures included technical and
clinical success, overall complications, stent patency and
reintervention rate; (5) when multiple articles published
by the same team from the same institute within the
same study interval were identified, only the latest or the
most detailed and informative article, or the one with the
best quality in methodology, was included. Commentaries,
case reports, reviews, or guidelines were excluded.
Data extraction
Two reviewers (YM.P and J.P) abstracted data inde-
pendently and reached consensus on all items. Data
were extracted on: first author; year of publication;
study interval; number of patients; age and sex; study
design, stent characteristics; technical success rate; clinical
success rate; stent obstruction; stent migration; overall
complications; reintervention rate; stent patency and GOO
scoring system (GOOSS).
Assessment of methodological quality
The quality of all studies was assessed by using the
Newcastle-Ottawa Scale with some modifications to
match the needs for this meta-analysis [9]. The quality
of the studies was evaluated by examining three items:
patient selection, comparability of study groups, and
assessment of outcome. Studies achieving five or more
stars were considered high quality. Methodological quality
assessment was independently carried out by two of the
authors. Any disagreement was resolved by consensus.
Statistical analysis
Statistical manipulation was performed with Review
Manager Software (Version 5.1, Windows, Nordic Cochrane
Center, Copenhagen, Denmark). Values for analysis were
extracted from published reports or calculated from crude
data. For summary statistics in meta-analyses, the RelativeRisk (RR) is recommended for dichotomous data, and the
Weighted Mean Difference (WMD) is recommended for
continuous data. Pooled estimates were presented with a
95% confidence interval. P < 0.05 was considered significant.
A sensitivity analysis [10] determined how the results would
be influenced if one study was removed from the analysis
for each outcome; this indicates the extent to which the re-
sults are (or are not) robust to assumptions and decisions
that were made when carrying out the synthesis. Because of
the anticipated clinical heterogeneity across the included
studies, we decided to use only the random effect model
before pooling data. This adjusts for variability of results
among studies and provides a more conservative estimate
of an effect by using a wider confidence interval [11].
Results
Identification of eligible studies
The literature search yielded 382 abstracts for review.
Finally, 9 trials [5-7,12-17] were included (Figure 1). 3
trials [5,14,16] were randomized clinical trials, 5 trials
[6,7,12,15,17] were retrospective studies and one re-
port [13] was prospective study. The combined studies
enrolled 849 patients, of whom 380 underwent covered
stents placement and 469 with uncovered stents. The
characteristics of included trials were listed in Table 1.
The quality assessment and scores are summarized in
Table 1. Seven studies scored five or more stars on the
modified Newcastle Ottawa Scale [5,12-17]. Characteristics
of stents were not consistent in all studies (Table 2). More
than two types of stents were used in 3 trials [14,15,17].
Table 1 Characteristics of the included studies












Yu Kyung Cho [5] 2004 RCT NR 13/12 65.0§ 12(48%) GC(25) 1,2,3 *****
Jong Pil Im [6] 2008 R 2005-2006 24/18 60.7§ 7(16%) GC(26)/PC(12)
/Others(13)
NR ****
Seungmin Bang [7] 2008 R 1998-2003 53/79 58.0/59.0 40(30%) GC(109)/PC(13)
/Others(12)
NR ***
Iruru Maetani [12] 2009 R 1998-2006 29/31 70.6/72.2 27(45%) GC(28)/PC(20)/
Others(12)
1,2,3,4,5 *****
Kee Myung Lee [13] 2009 P 1998-2007 70/84 67.2/63.3 48(31%) GC(122)/PC(19)
/Others(13)
1,2,3,5 *****
Chan Gyoo Kim [14] 2010 RCT 2003-2007 40/40 58.0/57.0 17(21%) GC(80) 1,2,3,4,5 ******
Chan Ik Park [15] 2012 R 2006-2011 96/128 64.0/65.0 15(17%) GC(224) 1,2,5 *****
Iruru Maetani [16] 2013 RCT 2007-2010 31/31 69.4/68.1 32(52%) GC(27)/PC(26)
/Others(9)
1,2,3,4,5 ******
Sang Myung Woo [17] 2013 R 2003-2010 24/46 62.0/61.0 30(43%) PC(46) /Others(24) 1,2,3,4,5 *****
R, retrospective; P, prospective; RCT, randomized control trial; NR, not reported.
§, mean age of all patients; (*), star rating (max 9).
Matching: 1, age; 2, sex; 3, diagnosis; 4, site of obstruction; 5, previous treatment.
GC, gastric cancer; PC, pancreatic cancer.
Others, including gallbladder cancer, bile duct cancer, ampullary cancer, duodenal cancer and metastasis.
Pan et al. BMC Gastroenterology 2014, 14:170 Page 3 of 8
http://www.biomedcentral.com/1471-230X/14/170The main composition of covered materials is polytetra-
fluoroethylene membrane or polyurethane membrane.
Technical and clinical success rate
All trials assessed the technical success rate related to
stenting procedure, and 6 trials [12-17] assessed the
clinical success rate. Meta-analysis showed that there
was no significant difference in technical success rate
(RR 1.00, 95% CI [0.98, 1.01]) (Figure 2a) and clinical suc-
cess rate (RR 1.04, 95% CI [0.98, 1.11]) (Figure 2b). The
post-stenting GOOSS was recorded in 6 trials [5,12-16],
there was no significant difference between covered and
uncovered stents group (P = 0.96) (Figure 3a).
Stent patency
The stent patency was reported in 6 studies [6,13-17]. The
median patency duration was 9 to 23 weeks with covered
stents and 10 to 22 weeks with uncovered stents re-
spectively. Meta-analysis showed there was no signifi-
cant difference between covered and uncovered stents
group (WMD −0.31, 95% CI [−1.73, 1.11]) (Figure 3b).
Chemotherapy after endoscopic stenting was reported
in 6 studies, totally 42.7% (270/632) patients under-
went chemotherapy. All studies reported that palliative
chemotherapy was not associated with stent patency.
Complications and reintervention
Meta-analysis showed there were no significant difference
in overall complications between covered and uncovered
stents group (P = 0.54) (Figure 4c). However, covered
stents were associated with higher stent migration
(RR 3.48, 95% CI [2.16, 5.62]) (Figure 4a), and uncoveredstents were associated with higher stent obstruction
(RR 0.42, 95% CI [0.24, 0.73]) (Figure 4b) in subgroup
analysis. Reintervention for stent-related complications
was reported in 6 studies [5,12-15,17]. Meta-analysis
showed there was no significant difference in reinter-
vention rate between two groups (P = 0.13) (Figure 4d).
Sensitivity analysis
The results of sensitivity analysis are listed in Table 3. When
high quality studies were analyzed (Star ≥ 5), meta-analysis
showed there was no significant difference in technical
success rate, clinical success rate, stent patency, overall com-
plications, Post-stenting GOOSS and reinterventioon rate
between two groups. Covered stents were associated with
higher stent migration rate (RR 3.49, 95% CI [1.92, 6.32])
and lower stent obstruction rate (RR 0.39, 95% CI [0.18,
0.84]) compared to uncovered stents. In the studies contain-
ing N ≥ 70 patients, meta-analysis showed the same results.
Data were also analyzed by random effects models. Sensitiv-
ity analysis showed that the results were robust.
Discussion
Malignant gastric outlet obstruction without effective
intervention would result in progressive deterioration
and death [3]. Surgical bypass has been the standard
treatment, but it is associated with significantly high
morbidity and mortality. Endoscopic stenting is an al-
ternative treatment, which palliates malignant obstruction
with lower morbidity and mortality [4]. There are two types
SEMSs widely used in clinical, covered and uncovered.
Which is better? Maetani et al. [6] reported covered stents
were associated with more frequent need for reintervention
Table 2 Stent characteristics of the included studies
Study/author Group Stent type Stent material Stent diameter (mm) Stent length (cm) Covered material
Yu Kyung Cho Covered NR Nickel-Titanium NR NR NR
Uncovered Nickel-Titanium
Jong Pil Im Covered NR 18 9/11
Uncovered NR 18 11/12/16 NR
Seungmin Bang Covered Niti-S NR 20/22 6-15
Uncovered Niti-S 20/22 6-15 PU
Iruru Maetani Covered Ultraflex NR 18/23 10/12/15
Uncovered Ultraflex 18/23 10/12/15 PTFE
Kee Myung Lee Covered Niti-S Nitinol 18 6/8/10
Uncovered Niti-S Nickel-Titanium 18 6/8/10 PU
Chan Gyoo Kim Covered Niti-S Nitinol 18/20 8/10/12
Uncovered Wallstent/Wallflex Elgiloy/Nitinol 20/22 6/9/12 PTFE
Chan Ik Park Covered Niti-s Nitinol NR 6-16
Uncovered Wallstent/Hanaro Elgiloy/Nitinol 6-16 PU
Iruru Maetani Covered Niti-S Nitinol 20
Uncovered Comvi Nitinol 20 NR PTFE
Sang Myung Woo Covered Niti-s/Bona 18-22 4-12
Uncovered Niti-s/Bona/Wallflex NR 18-22 4-12 NR
PTEF, polytetrafluoroethylene; PU, polyurethane.
Niti-S (Taewoon Inc. South Korea); Bona (Standard SciTech Inc. Seoul, Korea).
Hanaro (M.I. Tech. Seoul, Korea).
Wallflex (Boston Scientific, USA); Wallstent (Boston Scientific, USA).
Ultraflex (Boston Scientific, USA).
Figure 2 Meta-analysis showed there was no significant difference in technical success rate (a) and clinical success rate (b) between
covered and uncovered stents group.
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Figure 3 Meta-analysis showed there was no significant difference in post-stenting GOOSS (a) and stent patency (b) between covered
and uncovered stents group.
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ered and uncovered SEMSs were effective and safe in treat-
ment of patients. Recently, a systematic review [8] on this
topic has been published. However, only two RCTs related
to GOO were included for analysis in this systematic re-
view, the number of included patients may be too small to
make effective statistic analysis. More recently, additional
studies have been published and some conflicting results
have emerged. Therefore, we believe an updated systemic
review and meta-analysis is required to evaluate the efficacy
and safety between uncovered and covered SEMSs.
In this meta-analysis, there was no significantly differ-
ence between uncovered and covered stents in technical
and clinical success rates. Endoscopic stenting was de-
ployed through a guide wire, when the guide wire could
not pass the stricture, and then the stent could not be
deployed successfully. So the success of stenting is af-
fected by the degree of narrowing and tortuosity of the
stricture rather than the difference between the types of
stent used.
The GOOSS was used to evaluate the severity of ob-
structive symptom, the GOOSS assigns a point score de-
pending on the patient’s level of oral intake (no oral
intake, 0; liquids only, 1; soft solids, 2; low-residue or full
diet, 3) [18]. Most of patients could not intake any fluid
before stenting, though most included studies were
retrospective, the patients’ characteristics were similar in
baseline. There was significant difference in GOOSS pre-
stenting and post-stenting, but there was no difference
between covered and uncovered stents after stenting.These mean that both stents have similar effect in palli-
ation of malignant obstruction.
Stent patency is an important factor in QOL of pa-
tients. Meta-analysis showed there was no significant
difference in stent patency between two groups. The
main cause influencing patency was stent migration in
covered stent group and stent obstruction in uncov-
ered stent group respectively. The covered stent was
associated with advantage of preventing tumor in-
growth, but this advantage was offsetted by high mi-
gration. Chemotherapy after stent placement could be
independently associated with prolonged stent pa-
tency, because chemotherapy may stabilize or decrease
tumor burden and thereby decrease malignant in-
growth or overgrowth. Some studies [19,20] reported
chemotherapy after stent placement contributed to longer
durations of stent patency in gastric cancer patients. How-
ever, we could not find any association of stent patency
with palliative chemotherapy after stent placement in in-
cluded studies. Further prospective randomized trials are
needed to determine the role of chemotherapy.
Complications included stent obstruction, stent migra-
tion, bleeding, stent fracture, perforation and others, the
most complications were stent obstruction and migra-
tion. There was no difference in overall complications
between the covered stent group and uncovered stent
group. One study [21] has shown that covered stents
placed in the biliary tract prevent tumor ingrowth with-
out increasing migration frequency. However, in sub-
group analysis, our meta-analysis showed that stent
Figure 4 Complications and reintervention between covered and uncovered metal stents group. Meta-analysis showed there was no
significant difference in overall complications (c). However, covered stents were associated with higher stent migration (a) and less restenosis
(b) compared to uncovered stents. There was no significant difference in reintervention rate between two groups (d).
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which is maybe the expansion force of the covered stent
is transferred to the intestinal wall through the covering
membrane rather than through the wire mesh, and the
friction between stent and tumor might not be enoughto keep the stent stationary. The cause of stent obstruction
included tumor ingrowth and overgrowth. Meta-analysis
showed uncovered stents were associated with higher stent
obstruction compared to covered stents, because uncovered
stents are often associated with tumor ingrowth through
Table 3 Sensitivity analysis





High quality studies(Star≥ 5)
Technical success rate 7 675 99.0/100 0.99 [0.98, 1.01] 0.51
Clinical success rate 6 650 91.4/85.8 1.04 [0.98, 1.11] 0.18
Post-stenting GOOSS 6 451 - −0.01 [−0.52, 0.50]* 0.96
Stent pantency 5 590 - −0.05 [−1.50, 1.39]* 0.94
Stent migration 7 662 16.3/3.3 3.49 [1.92, 6.32] <0.0001
Stent obstruction 7 662 6.8/20.4 0.39 [0.18, 0.84] 0.02
Overall complications 6 508 50.0/44.7 1.11 [0.86, 1.44] 0.43
Reintervention rate 6 600 21.3/16.3 1.30 [0.92, 1.83] 0.13
Studies containing ≥ 70 patients
Technical success rate 5 660 98.9/100 1.00 [0.98, 1.01] 0.53
Clinical success rate 4 528 92.6/84.6 1.08 [0.99, 1.18] 0.08
Post-stenting GOOSS 3 304 - 0.26 [−0.05, 0.48]* 0.06
Stent pantency 4 528 - 0.62 [−0.06, 1.18]* 0.07
Stent migration 5 647 20.1/4.3 4.00 [2.05, 7.80] <0.0001
Stent obstruction 5 647 6.6/20.6 0.35 [0.17, 0.74] 0.006
Overall complications 4 493 53.9/43.6 1.22 [0.99, 1.51] 0.06
Reintervention rate 4 515 21.7/17.7 1.25 [0.88, 1.78] 0.21
R, retrospective trial; P, prospective trial; RCT, randomized control trial.
*, WMD (95%CI).
GOOSS, gastric outlet obstruction scoring system.
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there was no significant difference between two groups.
When stent migration or stent obstruction occurred, endo-
scopic or surgical interventions should be taken. Though
3 trials reported uncovered stent was associated with
lower re-intervention rate, meta-analysis showed there
was no significant difference between covered and un-
covered stents.
Several limitations of the present study need to be
considered. First, there was significant heterogeneity
for main outcomes. The source of heterogeneity may
include the different publishing time of studies, the
study design (6 none-RCT studies), the selection cri-
teria, the characteristic of patients and stents. Though
the data was treated with random effect models, there
was still some influence to final results. Second,
included studies were associated with small sample
sizes, different levels of the intervention, different
follow-up duration; those could also influence the
results. Third, there were many different causes of
GOO, which including gastric cancer, pancreatic can-
cer and others. The different characteristic of diseases
might lead to different stent patency and complica-
tions. Fourth, the selective reporting of studies with
positive results may result in overestimation of technical,
clinical success rate and stent patency, and cause some
bias to our meta-analysis.Conclusions
Both covered and uncovered SEMSs are technically feas-
ible and effective in the palliative treatment of malignant
gastric outlet obstruction. Meta-analysis showed there was
no significant difference in stent patency, overall compli-
cations and reintervention; whereas in subgroup analysis,
stent obstruction was more frequent with covered stents,
and stent migration occurred more frequently with uncov-
ered stents. The retrospective nature of these reports
and their small sample sizes suggest that prospective
controlled trials with large sample sizes are required to
confirm the results of the current meta-analysis.
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